• 1
    Armuzzi A, Candelli M, Zocco MA, et al. Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther 2002; 16: 197796.
  • 2
    Hepner GW, Vesell ES. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 1974; 291: 13848.
  • 3
    Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med 1975; 83: 6328.
  • 4
    Geboes KP, Rutgeerts P, Verbeke K. Ademtesten in de gastroenterologie. Tijdschrift voor gastro-enterologie 2003; 41: 146.
  • 5
    Irving CS, Schoeller DA, Nakamura KI, Baker AL, Klein PD. The aminopyrine breath test as a measure of liver function. A quantitative description of its metabolic basis in normal subjects. J Lab Clin Med 1982; 100: 35673.
  • 6
    Baker AL, Kotake AN, Schoeller DA. Clinical utility of breath tests for the assessment of hepatic function. Semin Liver Dis 1983; 3: 31829.
  • 7
    Dinesen L, Caspary WF, Chapman RW, et al. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. Dig Liver Dis 2008; 40: 7438.
  • 8
    Petrolati A, Festi D, De Berardinis G, et al. 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. Aliment Pharmacol Ther 2003; 18: 78590.
  • 9
    Timbrell J. Principles of Biochemical Toxicology. 2nd ed, London: Taylor & Francis, 1991.
  • 10
    Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 142.
  • 11
    Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 2000; 10: 27990.
  • 12
    Van Der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 1999; 36 (Pt 6): 7229.
  • 13
    Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001; 58: 73747.
  • 14
    Afolabi P, Wright M, Wootton SA, Jackson AA. Clinical utility of 13C-liver-function breath tests for assessment of hepatic function. Dig Dis Sci 2013; 58: 3341.
  • 15
    Schoeller DA, Kotake AN, Lambert GH, Krager PS, Baker AL. Comparison of the phenacetin and aminopyrine breath tests: effect of liver disease, inducers and cobaltous chloride. Hepatology 1985; 5: 27681.
  • 16
    Brockmoller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994; 27: 21648.
  • 17
    Kajiwara M, Okazaki T, Iida K, et al. Studies on 13C-phenacetin metabolism. II. A combination of breath test and urine test of in vivo metabolites in the diagnosis of liver disease. Chem Pharm Bull (Tokyo) 1996; 44: 125860.
  • 18
    Ciccocioppo R, Candelli M, Di Francesco D, et al. Study of liver function in healthy elderly subjects using the 13C-methacetin breath test. Aliment Pharmacol Ther 2003; 17: 2717.
  • 19
    Braden B, Faust D, Sarrazin U, et al. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2005; 21: 17985.
  • 20
    Holtmeier J, Leuschner M, Schneider A, et al. 13C-methacetin and 13C-galactose breath tests can assess restricted liver function even in early stages of primary biliary cirrhosis. Scand J Gastroenterol 2006; 41: 133641.
  • 21
    Schneider A, Caspary WF, Saich R, et al. 13C-methacetin breath test shortened: 2-point-measurements after 15 minutes reliably indicate the presence of liver cirrhosis. J Clin Gastroenterol 2007; 41: 337.
  • 22
    Lara Baruque S, Razquin M, Jimenez I, et al. 13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease. Dig Liver Dis 2000; 32: 22632.
  • 23
    Razlan H, Marzuki NM, Tai ML, et al. Diagnostic value of the C methacetin breath test in various stages of chronic liver disease. Gastroenterol Res Pract 2011; 2011: 235796.
  • 24
    Palmieri VO, Grattagliano I, Minerva F, et al. Liver function as assessed by breath tests in patients with hepatocellular carcinoma. J Surg Res 2009; 157: 199207.
  • 25
    Park GJ, Katelaris PH, Jones DB, et al. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology 2003; 38: 122736.
  • 26
    Kotake AN, Schoeller DA, Lambert GH, et al. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32: 2619.
  • 27
    Park GJ, Katelaris PH, Jones DB, et al. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther 2005; 22: 395403.
  • 28
    Park G J, Wiseman E, George J, et al. Non-invasive estimation of liver fibrosis in Non-alcoholic fatty liver disease using the (13) C-caffeine breath test. J Gastroenterol Hepatol 2011; 26: 141116.
  • 29
    Brodie BB, Axelrod J. The fate of aminopyrine (pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material. J Pharmacol Exp Ther 1950; 99: 17184.
  • 30
    Volz M, Kellner HM. Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 1980; 10 (Suppl 2): 299S308S.
  • 31
    Agundez JA, Martinez C, Benitez J. Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 1995; 25: 41727.
  • 32
    Niwa T, Sato R, Yabusaki Y, Ishibashi F, Katagiri M. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica 1999; 29: 18793.
  • 33
    Noordhoek J, Dees J, Savenije-Chapel EM, Wilson JH. Output of 14CO2 in breath after oral administration of (14C-methyl) aminopyrine in hepatitis, cirrhosis and hepatic bilharziasis: its relationship to aminopyrine pharmacokinetics. Eur J Clin Pharmacol 1978; 13: 2239.
  • 34
    Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57: 46580.
  • 35
    Purba HS, Back DJ, Orme ML. Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors. Br J Clin Pharmacol 1987; 24: 2304.
  • 36
    Iguchi S, Goromaru T, Noda A. Communications to the editor: a new metabolite of aminopyrine (aminophenazone) in man, 4-formylaminoantipyrine. Chem Pharm Bull (Tokyo) 1975; 23: 9324.
  • 37
    Noda A, Goromaru T, Tsubone N, Matsuyama K, Iguchi S. In vivo formation of 4-formylaminoantipyrine as a new metabolite of aminopyrine. I. Chem Pharm Bull (Tokyo) 1976; 24: 15025.
  • 38
    Gradnik R, Fleischmann L. Quantitative urinary excretion of various aminopyrine metabolites in man. Pharm Acta Helv 1973; 48: 18191.
  • 39
    Schneider AR, Teuber G, Paul K, et al. Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection. Clin Exp Pharmacol Physiol 2006; 33: 3004.
  • 40
    Di Campli C, Angelini G, Armuzzi A, et al. Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation. Eur J Gastroenterol Hepatol 2003; 15: 72732.
  • 41
    Candelli M, Armuzzi A, Nista EC, et al. 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. Aliment Pharmacol Ther 2004; 19: 243.
  • 42
    Giannini E, Fasoli A, Chiarbonello B, et al. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16: 71725.
  • 43
    Caubet MS, Laplante A, Caille J, Brazier JL. [13C]aminopyrine and [13C]caffeine breath test: influence of gender, cigarette smoking and oral contraceptives intake. Isotopes Environ Health Stud 2002; 38: 717.
  • 44
    Ecochard M, Boillot O, Guillaud O, et al. Could metabolic liver function tests predict mortality on waiting list for liver transplantation? A study on 560 patients. Clin Transplant 2010; 25: 75565.
  • 45
    Degre D, Bourgeois N, Boon N, et al. Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transpl Int 2004; 17: 318.
  • 46
    Forestier J, Dumortier J, Guillaud O, et al. Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests. Eur J Gastroenterol Hepatol 2010; 22: 53240.
  • 47
    Giannini EG, Fasoli A, Borro P, et al. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 27985.
  • 48
    Braden B. Methods and functions: breath tests. Best Pract Res Clin Gastroenterol 2009; 23: 33752.
  • 49
    Kodaira C, Uchida S, Yamade M, et al. Influence of different proton pump inhibitors on activity of cytochrome P450 assessed by [(13)C]-aminopyrine breath test. J Clin Pharmacol 2012; 52: 4329.
  • 50
    Wijnen P A, Op Den Buijsch R A, Drent M, et al. Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther 2007; 26 (Suppl 2): 2119.
  • 51
    Flockhart DA. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin Pharmacokinet 1995; 29(Suppl 1): 4552.
  • 52
    Indiana University: P450 Drug Interaction Table. 2011. Available at Accessed 22 August 2013.